CLEO
20.5.2019 09:02:06 CEST | Business Wire | Press release
Gartner’s Application Architecture, Development & Integration (AADI) Summit returns to London to provide strategies for solving the pervasive challenges of orchestrating workflows between external B2B and application ecosystems with internal business systems. Cleo , the global leader in ecosystem integration solutions, will be exhibiting in Booth S3 to demonstrate how successful organisations leverage its “outside-in” approach to create seamless end-to-end workflows and help optimize business processes.
The Gartner AADI 2019 event , taking place 20-21 May at Park Plaza Westminster, is designed to empower IT and business professionals in transforming their application architecture, agile development, and integration strategies. The event’s focus on application strategies and data processes in the era of the cloud highlights the need for better ways to execute application integration, an inescapable challenge in today’s business landscape.
According to the 2019 State of Ecosystem and Integration Application Report , integration is a constant battle for organisations, with 25% of companies struggling to integrate new applications with legacy systems. All told, unreliable partner and application integrations are costing companies approximately $500,000 every year. Cleo will showcase at the Gartner AADI summit how to solve these challenges using an innovative approach that integrates the dynamic ecosystem of people, partners, customers, systems, applications, and things and supports the critical data flows driving revenue.
About Cleo Integration Cloud
Today’s data exchange requirements often are dictated by the partners, suppliers, customers, vendors, and all their respective technologies comprising a modern business ecosystem, and it demands a change in how we view traditional integration patterns. Conference-goers visiting the Cleo booth will learn hands-on about the business benefits of technology embracing this fresh POV – integration that prioritises external customer and trading partner data processes and integrates them seamlessly into internal workflows – via the Cleo Integration Cloud platform.
Cleo’s flagship offering is a single, hybrid integration platform enabling organisations to connect, transform, integrate, orchestrate, and analyse end-to-end application, B2B, cloud, and data integrations for improved visibility across global business ecosystems. Cleo Integration Cloud facilitates the heavy lifting of integration while also providing dynamic dashboards to empower technical and business users to make better decisions, create stronger relationships with trading partners, and accelerate growth as data requirements evolve. The result is end-to-end transparency throughout internal networks and external business ecosystems, which enables organisations to maximise the value of their application investments.
Agenda Highlights
The opening keynote for this year’s Gartner AADI summit is titled, “Optimize, Integrate and Transform to Achieve Your Digital Future” and features Gartner’s Elizabeth Golluscio, managing vice president, Keith Guttridge, senior director analyst, and Mark O'Neill, VP analyst. The speakers will explore how organisations pursuing digital transformation must apply modern digital application and integration strategies to advance those initiatives.
The agenda also features a number of topics spanning cloud integration challenges, strategic application trends, modernising core systems, postmodern ERP integration, and how smart application integration delivers next-generation customer experiences. The nature of the 2019 agenda further emphasizes the value an ecosystem-driven approach can have in designing application integration processes that support innovation, align with business goals, and deliver competitive advantage.
“Organisations are at a tipping point in how they integrate all the ERPs, CRMs, e-commerce, and other business-critical applications they deploy almost daily,” said Cleo CMO Tushar Patel . “It’s individual departments and lines of business that are driving technology investment, rather than the traditional IT teams, and it requires a change in how they approach application integration. Today’s integration technology should give companies a path to optimising their core business processes while solving external B2B and internal application integration challenges simultaneously.”
Patel adds: “The companies treating application and B2B interactions as separate, disparate business processes are leaving value on the table and will get left behind.”
Come see Cleo at Booth S3 for a Cleo-themed cocktail – an “Ecosystem Integration Elixir” – and to learn how Cleo customers are achieving success every day with Cleo Integration Cloud. To learn more about Cleo, and how Cleo Integration Cloud can help your business, visit our website – www.cleo.com .
For more insights on what to expect at the event, read the blog titled, “Ecosystem Integration & Value Beyond the Gartner AADI London Agenda.”
About Gartner AADI 2019
The Gartner Application Architecture, Development & Integration Summit 2019 is designed for application leaders to learn about crafting leading-edge applications, architectures and strategies leveraging microservices, DevOps and artificial intelligence, and more. Attendees can gain intensive learning and actionable insight as they plan to drive growth through digital business transformation.
About Cleo
Cleo is an ecosystem integration software company focused on business outcomes, ensuring each customer’s potential is realized by delivering solutions that make it easy to discover and create value through the movement and integration of enterprise data. Cleo gives customers a strategic, “outside-in” visibility into the critical end-to-end business flows happening across their ecosystems of partners and customers, marketplaces, and internal cloud and on-premise applications. Our solutions empower teams to drive business agility, accelerate onboarding, facilitate modernisation of key business processes, and capture new revenue streams by reimagining and remastering their digital ecosystem through robust application, B2B, and data integration technologies. For more information, visit www.cleo.com or call +1.815.282.7695.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005142/en/
Contact:
Media Contacts Matt Torman Senior Manager, Marketing Communications Cleo +1.815.282.7610
Drew Smith Senior Account Manager 10Fold Communications (for Cleo) +1.415.800.5374
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom